A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors

1. Previously received chemotherapy or radiotherapy, including but not limited to neoadjuvant chemoradiotherapy and/or adjuvant chemoradiotherapy.

2. Underwent bone marrow transplantation or stem cell transplantation.

3. Concurrently diagnosed with malignancies other than NSCLC.

4. Active central nervous system metastasis and/or carcinomatous meningitis, except for asymptomatic brain metastasis subjects (i.e., no progressive central nervous system symptoms caused by brain metastases, no need for corticosteroids, and lesion size ≤1.5 cm) are allowed.

5. Diagnosed with acute congestive heart failure, cardiomyopathy, or myocardial infarction by clinical, electrocardiogram, or other means.

6. Has a disease that may cause splenomegaly.

7. Associated with malignant hematological disorders.

8. Previously experienced sustained Grade ≥3 neutropenia (ANC \<1.0×10\^9/L) or febrile neutropenia lasting 3 days or more.

9. Underwent surgical procedures within the past 4 weeks and/or has an open wound.

10. Tumor involvement in the bone marrow.

11. Diagnosed with acute infections, chronic active hepatitis B within the past year (unless known negative for hepatitis B virus antigen before selection), or hepatitis C.

12. Pregnant or lactating women.

13. Known positive serum response to human immunodeficiency virus (HIV) or diagnosed with AIDS.

14. Active tuberculosis or recent history of contact with a tuberculosis patient unless tuberculin test is negative; or receiving treatment for tuberculosis; or suspected cases on chest X-ray.

15. Sickle cell anemia.

16. Known allergy to granulocyte colony-stimulating factors or drug excipients.

17. Rubber allergy.

18. Use of other investigational drugs within the past month before enrollment.

19. The investigator believes the participant has a disease or symptoms that make them unsuitable for participation in this study, and the investigational drug may harm the participant's health or affect the judgment of adverse events.

What this study is about